TRIPLE AGONIST COMPOUND
RU2026115366APending Publication Date: 2026-07-02CHENGDU AODA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- RU · RU
- Patent Type
- Applications
- Current Assignee / Owner
- CHENGDU AODA BIOTECHNOLOGY CO LTD
- Filing Date
- 2024-11-05
- Publication Date
- 2026-07-02
AI Technical Summary
Technical Problem
The side effects of existing GLP-1 compounds are difficult to achieve full-effect blood sugar control and weight loss. Natural GIP and GLP-1 are easily inactivated by the protease DPP IV, resulting in short-term metabolic control.
Method used
A GLP-1/GIP/GCG triagonist compound was developed to enhance its stability and activity by modifying the compound design, achieving long-term blood sugar control and weight loss.
Benefits of technology
This compound not only has better blood sugar control effects, but also significantly reduces weight and has the effect of treating non-alcoholic fatty liver.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention belongs to the field of pharmaceutical synthesis. Provided is a GLP-1 / GIP / GCG tri-agonist compound, the GLP-1 / GIP / GCG tri-agonist compound being used to prepare a pharmaceutical composition for treating diseases, and a use of the pharmaceutical composition in the preparation of a medicament for treating at least one of the following diseases, the treated diseases comprising type II diabetes, impaired glucose tolerance, type I diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcers, liver fibrosis, and pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art